South Africa to Produce Game-Changing HIV Prevention Drug

South Africa is taking a major step toward manufacturing a breakthrough HIV prevention drug on its own soil, potentially transforming access to lifesaving medication across the continent.

The South African government has partnered with Unitaid and the United States Pharmacopoeia to identify local pharmaceutical companies capable of producing lenacapavir. This twice-yearly injection has experts buzzing about its potential to help end the 44-year HIV pandemic.

Here's why this matters. South Africa has 8 million people living with HIV, more than any other nation. That's roughly one in every five adults. The country sits at the heart of the continent most affected by HIV, making local production a potential lifesaver for millions.

Last year, pharmaceutical giant Gilead Sciences awarded manufacturing licenses to six generic drug producers in India, Egypt, and Pakistan. Those companies can now supply lenacapavir to 120 developing nations, including South Africa. But critics noticed something important: no African manufacturers made the list.

A seventh license for a South African company could change everything. South Africa already has pharmaceutical expertise through companies like Aspen Pharmacare, which manufactures HIV treatments and sterile injectable medications. The infrastructure exists. Now it's about meeting quality standards and securing the partnership.

Gilead has signaled openness to the idea. The company said it will review proposals and assess whether quality standards can be met before granting any new voluntary license.

The Ripple Effect

This isn't just about South Africa. Kenyan President William Ruto, who leads African Union efforts on local health manufacturing, put it plainly: "Africa can no longer rely on medicines produced elsewhere for diseases that affect us most."

Deputy President Paul Mashatile echoed this vision. He emphasized that domestic production would benefit the entire African region, not just South Africa.

The potential impact extends even further. Current licensing agreements exclude middle-income nations like Brazil. A South African manufacturer could potentially help expand access to these countries too, according to Unitaid officials.

For decades, developing countries waited years to access HIV medications readily available in wealthier nations. While lenacapavir is currently available in some African countries through programs supported by The Global Fund and the U.S. government, demand is expected to exceed supply until generic manufacturers ramp up production.

Local manufacturing could help close that gap faster, putting a game-changing prevention tool directly in the hands of the communities that need it most.